Fig. 2.

NIR imaging of a basal cell carcinoma from the 3 mg cohort (top row) and an amelanotic melanoma in situ from the 6 mg cohort (bottom row). (A, D) Clinical photographs. The image in panel A was adjusted for color balance and brightness. (B, E) NIR images taken before BLZ-100 administration. The arrows are paper pointers with fluorescing pigment indicating the clinically identified lesion. (C, F) NIR images (500 msec exposures) acquired 2 h after dosing with BLZ-100. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)